SCHEMBL682822

SCHEMBL682822

COc1cccc(N2CCN(Cn3cnc4c3c(=O)n(C)c(=O)n4C)CC2C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 6/20 0.57
TP53 P04637 1/20 0.57
HTR7 P34969 1/20 0.47
HTR6 P50406 1/20 0.47
MAOB P27338 3/20 0.45
MAPK1 P28482 1/20 0.44
PKM P14618 1/20 0.43
MAOA P21397 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 2/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
ADORA2B P29275 2/20 0.43
CASP1 P29466 1/20 0.43
GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683664 0.89 MAPK1 (0.56) RXFP1HTR7HTR6MAPK1L3MBTL1
SCHEMBL684045 0.89 MAPT (0.50) RXFP1TP53HTR7HTR6MAPK1
SCHEMBL683994 0.85 RXFP1 (0.63) RXFP1TP53HTR7HTR6MAOB
SCHEMBL683707 0.85 ADORA2B (0.45) RXFP1TP53MAPK1SMN1; SMN2HTT
Hydrochloric Acid SCHEMBL11153642 0.79 HTR7 (0.61) RXFP1HTR7HTR6MAPK1L3MBTL1
SCHEMBL11156186 0.78 HTR7 (0.74) RXFP1TP53HTR7HTR6MAOB
SCHEMBL11153511 0.78 HTR7 (0.71) RXFP1HTR7HTR6MAPK1L3MBTL1
SCHEMBL684005 0.77 HTR7 (0.58) RXFP1TP53HTR7HTR6MAOB
SCHEMBL683604 0.76 RXFP1 (0.62) RXFP1TP53HTR7HTR6MAPK1
SCHEMBL683669 0.74 MAPK1 (0.45) MAPK1L3MBTL1SMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF RXFP1 211/4885TP53 4370/4885HTR7 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.